Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

ClinicalTrials.gov ID: NCT00017264

Public ClinicalTrials.gov record NCT00017264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Evaluation of the Safety and Pharmacokinetics of ABT-627 in Adults With Recurrent Malignant Gliomas

Study identification

NCT ID
NCT00017264
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
Not listed

Conditions and interventions

Interventions

  • atrasentan hydrochloride Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2002
Primary completion
Not listed
Completion
Not listed
Last update posted
Jan 12, 2009

Started 2002

United States locations

U.S. sites
10
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama 35294-3300
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612-9497
Winship Cancer Institute of Emory University Atlanta Georgia 30322
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231-2410
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Josephine Ford Cancer Center at Henry Ford Hospital Detroit Michigan 48202
Comprehensive Cancer Center at Wake Forest University Winston-Salem North Carolina 27157-1082
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195
Abramson Cancer Center at University of Pennsylvania Medical Center Philadelphia Pennsylvania 19104
University of Texas Health Science Center at San Antonio San Antonio Texas 78284-7811

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00017264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2009 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00017264 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →